X0306 4 2018-05-10 0 0001412486 Cocrystal Pharma, Inc. COCP 0001397607 Schinazi Raymond F 1860 MONTREAL ROAD TUCKER GA 30084 1 0 1 0 Common Stock 2018-05-10 4 M 0 263158 1.90 A 985384 I By LP Common Stock 2018-05-10 4 A 0 10209 1.90 A 995593 I By LP Common Stock 9240928 D 8% Convertible Note 8.10 2018-05-10 4 D 0 61728 500000 D 2017-11-24 2019-11-24 Common Stock 61728 61728 I By LP 8% Convertible Note 1.90 2018-05-10 4 A 0 263158 500000 A 2018-05-10 2019-11-24 Common Stock 263158 263158 I By LP 8% Convertible Note 1.90 2018-05-10 4 M 0 263158 500000 D 2018-05-10 2019-11-24 Common Stock 263158 263158 I By LP The amount of securities beneficially owned and the conversion prices have been adjusted for the one-for-30 reverse stock split effective January 24, 2018. The reporting person was issued common stock in connection with the conversion of a convertible note, as amended, at $1.90 per share. See Table II for a description of the convertible note. The reporting person was issued common stock in lieu of accrued interest owed in connection with the convertible note described in Table II. In accordance with Rule 16b-3, in advance of the effectuation of the transactions reported, the issuer's board of directors approved an amendment to the convertible note held by the reporting person who is a director and 10% beneficial owner of the issuer. The amendment of the outstanding convertible note is reported as a cancellation of the "old" note and the grant of a replacement note. /s/ Raymond F. Schinazi 2017-05-14